Latest Regulatory Milestones News

Ore Resources (ASX: OR3) has kicked off a 3,000m reverse circulation drilling campaign at its Coolgardie Lithium Projects, targeting strike extensions and infill at the Big Red and Potoroo pegmatites. The program follows strong historical lithium intercepts and promising metallurgical testwork, with results due in June 2026.

Arovella Therapeutics undergoes a major board overhaul and CEO resignation following a shareholder push, as the company embarks on a strategic review of its cell therapy platform.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

PYC Therapeutics presented Phase 1/2 data at ARVO 2026 showing encouraging safety and efficacy signals for its RNA therapies targeting rare genetic eye diseases Retinitis Pigmentosa type 11 and Autosomal Dominant Optic Atrophy.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.

PMET Resources has produced 4.47 tonnes of 6.09% Li2O spodumene concentrate at 89% recovery from its CV5 Pegmatite using an innovative DMS pilot program, bolstering its lithium project development and upcoming feasibility updates.

Energy Transition Minerals has released a JORC-compliant Mineral Resource Estimate for its Penouta tin-tantalum-niobium mine in Spain, reinforcing its strategic role in Europe's critical minerals supply chain and setting the stage for a project restart.

Magnetic Resources NL has reported significant new drilling results at its Lady Julie North 4 deposit, confirming multiple thick, high-grade gold zones and extending mineralisation down to 640m, with the resource remaining open at depth.

Brazilian Critical Minerals (ASX: BCM) has locked in pre-approval under Australia’s R&D Tax Incentive for its Ema Rare Earth Project, including critical overseas activities in Brazil. This reduces regulatory uncertainty and supports funding efficiency for advancing the project’s development.

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.

Sinowin Lithium, MRG Metals’ JV partner, will fund drilling at Corridor North in Mozambique, extending its investment beyond the 2 billion tonne Corridor Central and South projects targeting 2027 production and a ramp-up to 800,000 tonnes per annum.

RareX Limited has advanced its rare earths ambitions by securing a key mining lease at Cummins Range, appointing a strategic board member, and raising $5 million to fund exploration and development.